Clinical approaches to graft-versus-host disease (GVHD) will be the focus of one of the four abstract sessions on the Feb.13 Tandem Meetings agenda and among more than a dozen total oral abstract sessions included in this year’s program.

Oral Abstract – Session E – GVHD Clinical will begin at 3:15 p.m. on Feb. 13 in Ballroom B. When selecting the featured abstracts for this session, Session Co-chairs Betty Hamilton, MD,  Cleveland Clinic and Kate Markey, MBBS, PhD, FRACP, Fred Hutchinson Cancer Center, prioritized novel GVHD treatment strategies, existing drugs used in new ways, and cutting-edge scientific approaches.

“We are in an exciting time for GVHD management with new standards of care to both prevent and treat GVHD,” Hamilton and Markey explained. “However, there is continued room for improvement, particularly in improving toxicities and GVHD-related survival outcomes. Thus, it is important to continue to investigate novel approaches to improve outcomes.”

There are multiple FDA-approved therapies and standards of care for GVHD prevention, such as post-transplantation cyclophosphamide (PTCy) and abatacept, and GVHD treatment, such as ruxolitinib, but researchers continue to seek ways to improve outcomes and address concerns over toxicities.

“There are still patients who don’t respond to what we have, meaning it’s really important that we know what else is in the toolkit for the hardest cases,” the co-chairs explained.

The information in this session is geared toward anyone with an interest in GVHD, including clinical investigators, researchers, clinicians, trainees, pharmacists, nurses, and advanced practice providers. 

All abstract sessions will be available for on-demand viewing for registered 2025 Tandem Meetings participants following the meetings. Additional abstract sessions at the Tandem Meetings include:

• Oral Abstract – Session A – Leukemia and Relapse, 3:15 p.m. on Feb. 12
• Oral Abstract – Session B – Engineered Cells Clinical, 3:15 p.m. on Feb. 12
• Oral Abstract – Session C – Constrained Resource Settings, 3:15 p.m. on Feb. 12
• Oral Abstract – Session M – Gene Therapy, Study Design and Statistics, 3:15 p.m. on Feb. 12
• Oral Abstract – Session F – Myeloma and Lymphoma, 3:15 p.m. on Feb. 13, Ballroom C
• Oral Abstract – Session D – Toxicity and Supportive Care, 3:15 p.m. on Feb. 13, Ballroom A
• Oral Abstract – Session N – Hemoglobinopathies, Primary Immune Deficiencies, Inborn Errors of Immunity, and Stem Cell Biology, 3:15 p.m. on Feb. 13 in Room 316 ABC
• Oral Abstract – Session I – Basic Science, 3:15 p.m. on Feb. 14, Ballroom C
• Oral Abstract – Session G – Late Effects and Aging, 3:15 on Feb. 14 in Ballroom A
• Oral Abstract – Session H – Diversity and Graft Sources, 3:15 p.m. on Feb. 14, Ballroom B
• Oral Abstract – Session J – Relapse, 10:30 a.m. on Feb. 15 in Ballroom A
• Oral Abstract – Session K – Conditioning & Graft Sources, 10:30 a.m. on Feb. 15, Ballroom B
• Oral Abstract – Session L – Autoimmune Disease and Immune Reconstitution, 10:30 a.m. on Feb. 15, Ballroom C